
  
    
      
        
        The_DT AIDS_NNP crisis_NN has_VBZ brought_VBN to_TO public_JJ notice_NN what_WP has_VBZ always_RB been_VBN generally_RB true—that_NN
        the_DT existing_VBG business_NN model_NN for_IN drug_NN development_NN leads_VBZ to_TO high_JJ prices_NNS and_CC unequal_JJ access_NN ._.
        There_EX is_VBZ now_RB widespread_JJ dissatisfaction_NN with_IN drug_NN prices_NNS in_IN both_DT the_DT developed_VBN (_( Families_NNS
        USA_NNP 2003_CD )_) and_CC developing_VBG world_NN (_( Correa_NNP 2000_CD )_) ._. Governments_NNS and_CC health_NN insurers_NNS are_VBP finding_VBG
        ways_NNS to_TO deny_VB access_NN to_TO the_DT newest_JJS and_CC priciest_JJS products_NNS ._. In_IN the_DT United_NNP States_NNPS and_CC other_JJ
        countries_NNS without_IN a_DT universal_JJ public_JJ health_NN system_NN ,_, the_DT uninsured_JJ simply_RB cannot_NN afford_VBP the_DT
        newest_JJS medicines_NNS ._. In_IN developing_VBG countries_NNS ,_, life-saving_JJ medicines_NNS are_VBP priced_VBN beyond_IN the_DT
        reach_NN of_IN most_JJS people_NNS ,_, a_DT morally_RB offensive_JJ outcome_NN (_( TrueVisionTV_NNP 2003_CD )_) ._. Huge_JJ publicity_NN
        surrounds_NNS negotiated_VBD price_NN reductions_NNS for_IN specific_JJ drugs_NNS in_IN specific_JJ developing_NN countries_NNS ,_,
        yet_RB the_DT effect_NN on_IN the_DT overall_JJ access_NN problem_NN is_VBZ tiny_JJ ._.
        Today_NN 's_POS high_JJ drug_NN prices_NNS are_VBP a_DT direct_JJ consequence_NN of_IN a_DT business_NN model_NN that_WDT uses_VBZ a_DT single_JJ
        payment_NN to_TO cover_VB both_DT the_DT cost_NN of_IN manufacture_NN of_IN a_DT drug_NN and_CC the_DT cost_NN of_IN the_DT research_NN and_CC
        development_NN (_( R_NN &_CC D_NNP )_) carried_VBD out_IN by_IN manufacturers_NNS to_TO discover_VB it_PRP ._. A_DT 20_CD -_: year_NN patent-based_JJ
        marketing_NN monopoly_NN is_VBZ then_RB granted_VBN to_TO the_DT drug_NN 's_POS developers_NNS to_TO prevent_VB their_PRP$ prices_NNS being_VBG
        undercut_VBN by_IN ‘ generic_JJ’ copies_NNS produced_VBN by_IN manufacturers_NNS who_WP do_VBP not_RB have_VB R_NN &_CC D_NNP costs_NNS to_TO
        recover_VB ._. Preventing_NNP such_JJ ‘ free_JJ riding_NN’ on_IN R_NN &_CC D_NNP has_VBZ become_VBN a_DT global_JJ trade_NN issue_NN at_IN the_DT
        World_NNP Trade_NNP Organisation_NNP (_( WTO_NNP )_) (_( Drahos_NNP and_CC Braithwaite_NNP 2002_CD )_) ._. The_DT implementation_NN of_IN the_DT
        TRIPS_NNP (_( Trade-_NNP Related_NNP Aspects_NNP of_IN Intellectual_NNP Property_NNP Rights_NNP )_) agreement_NN and_CC a_DT growing_VBG
        number_NN of_IN regional_JJ and_CC bilateral_JJ agreements_NNS on_IN intellectual_JJ property_NN require_VB most_JJS countries_NNS
        to_TO implement_VB tough_JJ patent_NN systems_NNS that_WDT discourage_VBP or_CC eliminate_VB competition_NN from_IN
        manufacturers_NNS of_IN generic_JJ medicines_NNS (_( Box_NNP 1_LS )_) ._.
        Unfortunately_RB ,_, monopoly-based_JJ business_NN models_NNS have_VBP unpleasant_JJ side_NN effects_NNS ._. Since_IN the_DT
        primary_JJ responsibility_NN of_IN any_DT company_NN is_VBZ to_TO maximise_NN return_NN on_IN investment_NN ,_, it_PRP is_VBZ
        unsurprising_JJ that_IN there_EX is_VBZ pressure_NN on_IN pharmaceutical_JJ companies_NNS to_TO set_VB drug_NN prices_NNS to_TO
        whatever_WDT level_VBP gives_VBZ the_DT highest_JJS return_NN ,_, excluding_VBG those_DT individuals_NNS who_WP cannot_NN afford_VB to_TO
        pay_VB ,_, rather_RB than_IN maximising_VBG the_DT number_NN of_IN patients_NNS treated_VBN ._. There_EX is_VBZ also_RB pressure_NN to_TO
        misuse_NN the_DT power_NN given_VBN by_IN patents_NNS ,_, using_VBG them_PRP as_IN anticompetitive_JJ weapons_NNS to_TO block_VB
        innovation_NN and_CC extend_VB marketing_NN monopolies_NNS ._. And_CC there_EX are_VBP growing_VBG fears_NNS that_IN the_DT huge_JJ
        growth_NN in_IN the_DT use_NN of_IN patents_NNS is_VBZ in_IN itself_PRP starting_VBG to_TO inhibit_VB research_NN (_( CIPR_NNP 2002_CD ;_:
        Anonymous_NNP 2003_CD ;_: Royal_NNP Society_NNP 2003_CD )_) ._. Something_NN that_WDT is_VBZ less_RBR well_RB recognised_JJ is_VBZ that_IN this_DT
        system_NN is_VBZ an_DT enormously_RB inefficient_JJ way_NN of_IN purchasing_VBG R_NN &_CC D_NNP ._. There_EX is_VBZ a_DT considerable_JJ lack_NN
        of_IN transparency_NN in_IN pharmaceutical_JJ R_NN &_CC D_NNP investment_NN ,_, but_CC the_DT available_JJ data_NN indicate_VBP that_IN
        only_RB about_IN 10_CD %_NN of_IN drug_NN sales_NNS go_VBP towards_IN R_NN &_CC D_NNP on_IN new_JJ products_NNS ._. Only_RB about_IN one-quarter_NN of_IN
        new_JJ drug_NN approvals_NNS are_VBP rated_VBN by_IN the_DT United_NNP States_NNPS Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) to_TO
        have_VB therapeutic_JJ benefit_NN over_IN existing_VBG treatments_NNS (_( NIHCM_NNP 2002_CD ;_: see_VB Figure_NN 1_LS )_) ._. Measured_VBN by_IN
        investment_NN ,_, only_RB about_IN one-fifth_NN of_IN the_DT 10_CD %_NN is_VBZ invested_VBN in_IN innovative_JJ products_NNS (_( Love_NN
        2003_CD a_DT )_) ._. There_EX is_VBZ also_RB very_RB little_JJ research_NN for_IN diseases_NNS that_WDT primarily_RB afflict_VB the_DT poor_JJ
        (_( Trouiller_NNP et_CC al_NN ._. 2001_CD ;_: WHO_WP 2003_CD )_) ._.
        Propping_NNP up_RP the_DT present_JJ structure_NN for_IN financing_NN R_NN &_CC D_NNP (_( Figure_NN 2_CD A_DT )_) is_VBZ the_DT widely_RB held_VBN
        belief_NN that_IN the_DT private_JJ sector_NN plays_VBZ a_DT key_JJ role_NN in_IN the_DT development_NN of_IN new_JJ medicines_NNS and_CC
        that_IN it_PRP is_VBZ necessary_JJ to_TO grant_VB patents_NNS to_TO incentivise_NN private-sector_JJ financing_NN ._. If_IN this_DT were_VBD
        true_JJ ,_, it_PRP would_MD make_VB sense_NN to_TO tolerate_VB all_DT sorts_NNS of_IN bad_JJ outcomes_NNS ,_, because_IN the_DT fruits_NNS of_IN
        R_NN &_CC D_NNP eventually_RB benefit_NN everyone_NN ._. But_CC granting_VBG a_DT 20_CD -_: year_NN marketing_NN monopoly_NN on_IN a_DT
        patented_VBN invention_NN is_VBZ only_RB one_CD way_NN to_TO finance_VB R_NN &_CC D_NNP ,_, and_CC the_DT shortcomings_NNS of_IN the_DT present_JJ
        system_NN are_VBP increasingly_RB hard_JJ to_TO ignore_VB ._. Suggestions_NNP for_IN alternatives_NNS are_VBP beginning_VBG to_TO come_VB
        from_IN many_JJ quarters_NNS (_( Baker_NNP and_CC Chatani_NNP 2002_CD ;_: CGSD_NNP 2003_CD ;_: Hubbard_NNP and_CC Love_NN 2003_CD ;_: Weisbrod_NNP
        2003_CD )_) ._. In_IN this_DT essay_NN ,_, we_PRP present_JJ practical_JJ proposals_NNS to_TO modify_VB trade_NN rules_NNS based_VBN solely_RB on_IN
        intellectual_JJ property_NN so_IN that_DT alternative_JJ policy_NN instruments_NNS can_MD be_VB used_VBN to_TO encourage_VB
        innovation_NN ._.
      
      
        A_DT New_NNP Trade_NNP Framework_NNP
        Analysis_NNP of_IN worldwide_NN drug_NN expenditure_NN shows_VBZ that_DT spending_NN varies_VBZ ,_, but_CC is_VBZ close_JJ to_TO 1_CD %_NN of_IN
        the_DT gross_JJ domestic_JJ product_NN (_( GDP_NNP )_) in_IN most_RBS developed_VBN and_CC developing_VBG countries_NNS (_( Love_NN 2003_CD b_SYM )_) ._.
        Assuming_VBG that_IN about_IN a_DT tenth_NN of_IN the_DT revenue_NN from_IN the_DT sale_NN of_IN drugs_NNS is_VBZ ploughed_JJ back_RB into_IN
        R_NN &_CC D_NNP on_IN new_JJ products_NNS ,_, that_WDT means_VBZ that_IN countries_NNS already_RB indirectly_RB contribute_VB about_IN 0_CD ._. 1_CD %_NN
        GDP_NNP to_TO support_VB this_DT ._. This_DT contribution_NN is_VBZ enforced_VBN by_IN trade_NN agreements_NNS ,_, which_WDT require_VBP the_DT
        granting_VBG of_IN patents_NNS to_TO prevent_VB ‘ free_JJ riding_NN’ via_IN the_DT purchase_NN of_IN generic_JJ drugs_NNS (_( see_VB Box_NNP 1_LS )_) ._.
        Suppose_VB the_DT World_NNP Health_NNP Organisation_NNP (_( WHO_WP )_) developed_VBD an_DT R_NN &_CC D_NNP contribution_NN ‘ norm_NN’ based_VBN
        upon_IN this_DT or_CC a_DT more_RBR appropriate_JJ figure_NN and_CC that_IN there_EX was_VBD international_JJ agreement_NN that_IN
        countries_NNS evaluated_VBN as_IN meeting_VBG this_DT norm_NN would_MD no_RB longer_RB be_VB regarded_VBN as_IN ‘ free_JJ riding_NN’ ._.
        Trade_NN rules_NNS could_MD then_RB be_VB modified_VBN to_TO allow_VB countries_NNS to_TO meet_VB this_DT norm_NN 
        by_IN any_DT means_NNS ,_, not_RB just_RB by_IN the_DT implementation_NN of_IN strict_JJ TRIPS_NNP
        intellectual_JJ property_NN rules_NNS ,_, as_IN at_IN present_NN ._.
        Countries_NNS that_WDT met_VBD the_DT norm_NN would_MD then_RB be_VB free_JJ to_TO decide_VB whether_IN they_PRP wanted_VBD to_TO follow_VB a_DT
        strictly_RB patent-based_JJ system_NN as_IN at_IN present_JJ ,_, with_IN high_JJ drug_NN prices_NNS for_IN 20_CD years_NNS ,_, or_CC
        experiment_NN with_IN new_JJ models_NNS based_VBN on_IN the_DT creation_NN of_IN separate_JJ competitive_JJ markets_NNS for_IN sales_NNS
        and_CC R_NN &_CC D_NNP (_( Figure_NN 2_CD B_NNP )_) ._. Countries_NNS adopting_VBG the_DT latter_JJ system_NN would_MD remove_VB patents_NNS on_IN final_JJ
        drug_NN compounds_NNS ,_, placing_VBG them_PRP in_IN the_DT public_JJ domain_NN ._. This_DT would_MD allow_VB them_PRP to_TO become_VB a_DT freely_RB
        traded_VBN commodity_NN ,_, creating_VBG a_DT competitive_JJ manufacture_NN and_CC sales_NNS market_NN with_IN low_JJ generic_JJ
        prices_NNS ._. At_IN the_DT same_JJ time_NN ,_, in_IN order_NN to_TO meet_VB the_DT required_JJ R_NN &_CC D_NNP contribution_NN norm_NN ,_, they_PRP
        would_MD have_VB to_TO create_VB an_DT efficient_JJ R_NN &_CC D_NNP virtual_JJ market_NN alongside_IN ._. However_RB ,_, the_DT costs_NNS of_IN
        this_DT would_MD be_VB more_RBR than_IN offset_VBN by_IN the_DT reduction_NN in_IN drugs_NNS prices_NNS ,_, making_VBG substantial_JJ savings_NNS
        for_IN that_DT country_NN overall_JJ ._.
      
      
        Business_NNP Models_NNP for_IN an_DT Effective_NNP Virtual_NNP R_NNP &_CC D_NNP Market_NNP
        The_DT existing_VBG system_NN (_( Figure_NN 2_CD A_DT )_) ,_, despite_IN its_PRP$ failings_NNS ,_, does_VBZ lead_VB to_TO the_DT development_NN of_IN
        new_JJ drugs_NNS ._. The_DT challenge_NN in_IN creating_VBG a_DT virtual_JJ R_NN &_CC D_NNP market_NN is_VBZ to_TO find_VB viable_JJ business_NN
        models_NNS for_IN successful_JJ drug_NN development_NN in_IN the_DT absence_NN of_IN marketing_VBG monopoly_NN incentives_NNS ._.
        One_CD obvious_JJ approach_NN is_VBZ direct_JJ funding_NN of_IN drug_NN development_NN ._. For_IN example_NN ,_, the_DT National_NNP
        Institutes_NNPS of_IN Health_NNP (_( NIH_NNP )_) ,_, the_DT national_JJ agency_NN in_IN the_DT United_NNP States_NNPS ,_, already_RB spends_VBZ $_$ 27_CD
        billion_CD per_IN year_NN on_IN research_NN ,_, a_DT substantial_JJ amount_NN of_IN which_WDT is_VBZ directed_VBN towards_IN drug_NN
        development_NN ,_, including_VBG clinical_JJ trials_NNS ._. The_DT NIH_NNP already_RB has_VBZ a_DT track_NN record_NN in_IN developing_VBG
        important_JJ drugs_NNS for_IN severe_JJ illnesses_NNS ,_, such_JJ as_IN cancer_NN or_CC AIDS_NNP ,_, showing_VBG that_IN this_DT is_VBZ a_DT viable_JJ
        model_NN ._. It_PRP is_VBZ also_RB widely_RB recognised_JJ that_IN much_JJ of_IN the_DT research_NN carried_VBD out_IN across_IN the_DT world_NN
        by_IN similar_JJ agencies_NNS underpins_NNS the_DT existing_VBG commercial_JJ research_NN that_WDT leads_VBZ to_TO new_JJ drugs_NNS ._.
        Governments_NNS could_MD expand_VB direct_JJ funding_NN for_IN drug_NN development_NN ,_, either_CC through_IN the_DT
        existing_VBG structures_NNS in_IN academia_NN or_CC through_IN funding_NN R_NN &_CC D_NNP arms_NNS of_IN existing_VBG companies_NNS to_TO
        carry_VB out_IN specific_JJ drug_NN R_NN &_CC D_NNP ._. Such_JJ directed_VBN drug_NN development_NN funding_NN could_MD be_VB similar_JJ to_TO
        existing_VBG nonprofit_JJ development_NN projects_NNS ,_, such_JJ as_IN those_DT currently_RB resourced_JJ to_TO address_VB
        treatments_NNS for_IN neglected_VBN diseases_NNS like_IN malaria_NN and_CC tuberculosis_NNS (_( TB_NN )_) ._. Examples_NNS of_IN such_JJ
        projects_NNS are_VBP the_DT Medicines_NNP for_IN Malaria_NNP Venture_NNP (_( www_NN ._. mmv_NN ._. org_NN )_) ,_, the_DT Global_NNP Alliance_NNP for_IN TB_NN
        Drug_NNP Development_NNP (_( www_NN ._. tballiance_NN ._. org_NN )_) ,_, the_DT International_NNP AIDS_NNP Vaccine_NNP Initiative_NNP
        (_( www_NN ._. iavi_NN ._. org_NN )_) ,_, the_DT Drugs_NNS for_IN Neglected_NNP Diseases_NNP Initiative_NNP (_( Butler_NNP 2003_CD b_SYM )_) (_( www_NN ._. dndi_NN ._. org_NN )_) ,_,
        and_CC the_DT Institute_NNP for_IN One_CD World_NNP Health_NNP (_( www_NN ._. oneworldhealth_NN ._. org_NN )_) ._.
        Many_JJ are_VBP doubtful_JJ that_WDT increased_VBD direct_JJ funding_NN would_MD generate_VB sufficient_JJ incentives_NNS or_CC
        be_VB managed_VBN efficiently_RB enough_RB ._. An_DT alternative_NN market-based_JJ approach_NN is_VBZ one_CD in_IN which_WDT R_NN &_CC D_NNP
        organisations_NNS compete_VBP for_IN rewards_NNS for_IN specific_JJ R_NN &_CC D_NNP output_NN ,_, referred_VBD to_TO by_IN economists_NNS as_IN
        a_DT prize_NN model_NN (_( Wright_NNP 1983_CD ;_: Kremer_NNP 1998_CD ;_: Shavell_NNP and_CC van_NN Ypersele_NNP 2001_CD )_) ._. In_IN a_DT simple_JJ
        formulation_NN ,_, governments_NNS would_MD place_VB large_JJ sums_NNS into_IN a_DT fund_NN that_WDT would_MD be_VB allocated_VBN every_DT
        year_NN to_TO firms_NNS that_WDT bring_VBP new_JJ products_NNS to_TO market_VB ._. This_DT could_MD work_VB with_IN or_CC without_IN patents_NNS ._.
        If_IN products_NNS were_VBD protected_VBN by_IN patents_NNS or_CC other_JJ intellectual_JJ property_NN claims_NNS ,_, the_DT government_NN
        could_MD grant_VB compulsory_JJ licenses_NNS (_( a_DT procedure_NN allowed_VBN by_IN trade_NN agreements_NNS to_TO override_VB
        monopoly_NN rights_NNS on_IN a_DT patent_NN ,_, in_IN return_NN for_IN compensation_NN to_TO rights_NNS owners_NNS ;_: see_VB Box_NNP 1_LS )_) and_CC
        permit_VB rapid_JJ introduction_NN of_IN generic_JJ competition_NN ._. The_DT reward_NN system_NN could_MD be_VB a_DT lump-sum_JJ
        payment_NN ,_, eliminating_VBG any_DT incentive_NN to_TO continue_VB to_TO market_VB the_DT product_NN ,_, or_CC a_DT long-term_JJ payout_NN
        structure_NN ,_, which_WDT would_MD depend_VB upon_IN evidence_NN of_IN both_DT usage_NN and_CC efficacy_NN ._. Prize_NNP systems_NNS could_MD
        be_VB designed_VBN to_TO be_VB fairly_RB similar_JJ to_TO the_DT current_JJ system_NN ,_, with_IN big_JJ payoffs_NNS for_IN successful_JJ
        entrepreneurs_NNS ,_, but_CC even_RB with_IN this_DT approach_NN ,_, there_EX would_MD be_VB huge_JJ opportunities_NNS to_TO improve_VB
        welfare_NN ._. The_DT reward_NN system_NN could_MD be_VB more_RBR rational_JJ than_IN the_DT existing_VBG system_NN ,_, allocating_VBG
        greater_JJR rewards_NNS for_IN innovative_JJ products_NNS and_CC less_JJR for_IN ‘ me_PRP too_RB’ products_NNS that_WDT do_VBP not_RB work_VB
        better_JJR than_IN existing_VBG products_NNS ._. Premiums_NNP could_MD be_VB given_VBN for_IN therapies_NNS that_WDT address_VBP treatment_NN
        gaps_NNS or_CC for_IN inventions_NNS that_WDT pave_VB the_DT way_NN to_TO new_JJ classes_NNS of_IN drugs_NNS ._.
        Organisations_NNP competing_VBG for_IN prizes_NNS might_MD be_VB expected_VBN to_TO behave_VB secretly_RB to_TO ensure_VB that_IN
        they_PRP are_VBP the_DT ones_NNS to_TO obtain_VB ‘ credit_NN’ for_IN the_DT fruits_NNS of_IN their_PRP$ work_NN ._. However_RB ,_, progress_NN in_IN
        research_NN is_VBZ also_RB driven_VBN by_IN free_JJ exchange_NN of_IN information_NN ._. It_PRP may_MD be_VB possible_JJ to_TO design_VB
        models_NNS that_IN both_DT reward_NN R_NN &_CC D_NNP outputs_NNS and_CC at_IN the_DT same_JJ time_NN encourage_VB complete_JJ and_CC
        continuous_JJ openness_NN with_IN intermediate_JJ research_NN outputs_NNS ._. There_EX are_VBP now_RB a_DT number_NN of_IN examples_NNS
        of_IN open_JJ collaborative_JJ public_JJ goods_NNS models_NNS (_( Cukier_NNP 2003_CD )_) ,_, such_JJ as_IN those_DT used_VBN for_IN the_DT Human_NNP
        Genome_NNP Project_NNP ._. The_DT proponents_NNS of_IN such_JJ models_NNS point_VBP to_TO the_DT success_NN of_IN GNU_NNP /_NN Linux_NNP in_IN the_DT
        software_NN field_NN as_IN evidence_NN that_IN major_JJ projects_NNS can_MD be_VB undertaken_VBN with_IN radically_RB different_JJ
        business_NN models_NNS ._. One_CD of_IN the_DT benefits_NNS of_IN complete_JJ openness_NN is_VBZ that_IN it_PRP allows_VBZ independent_JJ and_CC
        open_JJ evaluation_NN of_IN R_NN &_CC D_NNP outputs_NNS ,_, which_WDT helps_VBZ in_IN the_DT allocation_NN of_IN ‘ credit_NN’ whether_IN in_IN
        the_DT form_NN or_CC prizes_NNS or_CC new_JJ research_NN grants_NNS ._. The_DT open-access_JJ publishing_NN movement_NN (_( Brown_NNP et_CC
        al_NN ._. 2003_CD )_) has_VBZ the_DT potential_NN to_TO help_VB in_IN this_DT process_NN by_IN allowing_VBG independent_JJ analysis_NN of_IN
        published_VBN science_NN ,_, which_WDT will_MD help_VB research_VB funding_NN agencies_NNS measure_NN research_NN outputs_NNS ._.
      
      
        Competitive_NNP Intermediators_NNP
        An_DT R_NN &_CC D_NNP contribution_NN norm_NN ,_, established_VBN by_IN treaty_NN ,_, would_MD ensure_VB that_IN the_DT amount_NN of_IN
        money_NN being_VBG spent_VBN on_IN R_NN &_CC D_NNP is_VBZ maintained_VBN ._. However_RB ,_, new_JJ mechanisms_NNS would_MD be_VB needed_VBN to_TO
        collect_VB the_DT money_NN to_TO finance_VB the_DT R_NN &_CC D_NNP ,_, as_IN it_PRP would_MD no_RB longer_RB come_VB via_IN drug_NN sales_NNS ._. This_DT
        could_MD be_VB via_IN general_JJ taxation_NN ,_, although_IN in_IN countries_NNS with_IN a_DT private_JJ health_NN insurance_NN system_NN
        this_DT may_MD be_VB anathema_NN ._. Many_JJ will_MD also_RB worry_VB that_IN a_DT centralised_JJ national_JJ drug_NN development_NN
        agency_NN taking_VBG decisions_NNS on_IN R_NN &_CC D_NNP priorities_NNS and_CC allocation_NN of_IN funds_NNS (_( via_IN prizes_NNS or_CC grants_NNS
        as_IN discussed_VBN above_IN )_) could_MD easily_RB become_VB bureaucratic_JJ and_CC inefficient_JJ ._.
        As_IN a_DT possible_JJ alternative_NN ,_, we_PRP propose_VBP a_DT competitive_JJ financing_NN scheme_NN that_WDT would_MD work_VB
        through_IN R_NN &_CC D_NNP investment_NN intermediators_NNS ._. These_DT R_NN &_CC D_NNP funds_NNS would_MD be_VB licensed_VBN and_CC
        regulated_VBN (_( like_IN pension_NN funds_NNS )_) ._. Their_PRP$ role_NN would_MD be_VB to_TO manage_VB R_NN &_CC D_NNP assets_NNS on_IN behalf_NN of_IN
        consumers_NNS ._. Individuals_NNS (_( or_CC employers_NNS )_) would_MD be_VB required_VBN to_TO make_VB minimum_JJ contributions_NNS into_IN
        R_NN &_CC D_NNP funds_NNS ,_, much_JJ as_IN there_EX are_VBP mandatory_JJ contributions_NNS to_TO social_JJ security_NN or_CC health_NN
        insurance_NN or_CC to_TO pension_NN funds_NNS ._. Government_NNP would_MD set_VB the_DT required_JJ contribution_NN ,_, but_CC the_DT
        individual_JJ (_( or_CC employer_NN )_) would_MD be_VB free_JJ to_TO choose_VB the_DT particular_JJ intermediator_NN that_WDT received_VBD
        their_PRP$ contributions_NNS ._. Intermediators_NNP would_MD compete_VB to_TO attract_VB funds_NNS to_TO invest_VB in_IN R_NN &_CC D_NNP on_IN
        the_DT basis_NN of_IN their_PRP$ prowess_NN for_IN drug_NN development_NN and_CC upon_IN their_PRP$ priorities_NNS ._. Different_JJ
        business_NN models_NNS for_IN financing_NN R_NN &_CC D_NNP could_MD be_VB tested_VBN in_IN such_JJ a_DT market_NN ,_, with_IN intermediators_NNS
        experimenting_VBG with_IN prize_NN systems_NNS ,_, direct_JJ investments_NNS in_IN profit_NN or_CC nonprofit_JJ entities_NNS ,_, open_JJ
        collaborative_JJ public_JJ good_JJ models_NNS ,_, or_CC other_JJ approaches_NNS ._.
      
      
        A_DT Change_NNP for_IN the_DT Common_NNP Good_JJ
        We_PRP believe_VBP the_DT economics_NNS of_IN a_DT change_NN in_IN the_DT paradigm_NN for_IN funding_NN R_NN &_CC D_NNP are_VBP highly_RB
        favourable_JJ ._. Taken_VBN together_RB ,_, the_DT two_CD core_NN steps_NNS of_IN changing_VBG the_DT trade_NN framework_NN and_CC moving_VBG
        away_RB from_IN marketing_NN monopolies_NNS can_MD change_VB the_DT world_NN in_IN a_DT positive_JJ way_NN ._. We_PRP can_MD raise_VB global_JJ
        R_NN &_CC D_NNP levels_NNS as_IN a_DT matter_NN of_IN policy_NN and_CC ensure_VB that_IN resources_NNS flow_VBP into_IN the_DT areas_NNS of_IN the_DT
        greatest_JJS need_VBP ,_, and_CC we_PRP can_MD do_VB so_RB knowing_VBG that_IN the_DT poor_JJ and_CC the_DT rich_JJ will_MD have_VB access_VB to_TO new_JJ
        inventions_NNS at_IN marginal_JJ cost_NN ._. Policy-makers_NNP will_MD be_VB weaned_JJ from_IN their_PRP$ current_JJ unhealthy_JJ
        addiction_NN to_TO ever-higher_JJ levels_NNS of_IN intellectual_JJ property_NN rights_NNS as_IN the_DT only_JJ instrument_NN to_TO
        raise_VB R_NN &_CC D_NNP levels_NNS ,_, a_DT path_NN that_WDT has_VBZ increasingly_RB reached_VBN diminishing_VBG returns_NNS or_CC become_VB
        counterproductive_JJ ._. With_IN new_JJ instruments_NNS to_TO address_VB the_DT overall_JJ levels_NNS of_IN R_NN &_CC D_NNP
        investment_NN ,_, policy-makers_NNS can_MD more_RBR constructively_RB address_VB the_DT well-known_JJ inefficiencies_NNS in_IN
        the_DT patent_NN system_NN without_IN the_DT fear_NN that_IN global_JJ R_NN &_CC D_NNP levels_NNS will_MD suffer_VB and_CC explore_VB
        alternative_JJ models_NNS (_( Butler_NNP 2003_CD a_DT )_) ._. At_IN the_DT same_JJ time_NN ,_, the_DT system_NN of_IN prescribing_VBG medicines_NNS
        will_MD be_VB transformed_VBN by_IN a_DT substantial_JJ reduction_NN in_IN the_DT distorting_VBG influences_NNS of_IN the_DT current_JJ
        multibillion-dollar_JJ industry_NN of_IN marketing_NN medicines_NNS to_TO doctors_NNS and_CC (_( increasingly_RB )_) directly_RB
        to_TO the_DT public_NN ._. Similarly_RB ,_, without_IN marketing_NN monopolies_NNS to_TO protect_VB ,_, there_EX will_MD be_VB far_RB less_JJR
        spent_VBD to_TO influence_VB the_DT governments_NNS that_WDT set_VBD the_DT rules_NNS that_WDT regulate_VB such_JJ monopolies_NNS ._. If_IN
        implemented_VBN worldwide_NN ,_, one_CD of_IN our_PRP$ most_RBS vexing_JJ ethical_JJ dilemmas_NNS can_MD be_VB resolved_VBN in_IN a_DT manner_NN
        that_WDT actually_RB promotes_VBZ the_DT Doha_NNP Declaration_NNP on_IN TRIPS_NNP and_CC Public_NNP Health_NNP mandate_NN to_TO encourage_VB
        access_NN to_TO medicine_NN for_IN all_DT ._.
      
      
        
      
    
  
